Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PRP shots show promise for thinning hair, but not a cure

NCT ID NCT07348315

Disease control Sponsor: zhang li Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting a person's own concentrated platelets (PRP) into the scalp can improve hair growth in men with male pattern baldness. Two hundred one men received 3 to 5 sessions of PRP injections. The main goal was to see if hair loss grade improved based on photos. While some men saw better hair quality and thickness, the treatment does not cure baldness and may require repeat sessions to maintain results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

201 people

The number who actually took part.

Started

Sep 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of hair loss for more than 6 months * Diagnosed with androgenetic alopecia (AGA) based on the Chinese guideline for diagnosis and treatment of AGA * In good general health with a body weight ≥ 50 kg * No history of hypertension, diabetes, platelet dysfunction, or any other contraindication to PRP apheresis * No use of finasteride, minoxidil, or any other treatment for hair loss within the 6 months preceding enrollment * No recent use of glucocorticoids (topical to treatment site for 1 month; systemic for 2 weeks) prior to PRP apheresis * No recent use of nonsteroidal anti-inflammatory drugs (within 48 hours) prior to PRP apheresis * Blood tests within 2 weeks before PRP apheresis meeting the following criteria: 1. Hemoglobin concentration \> 120 g/L 2. Hematocrit 0.30 to 0.50 3. Platelet count \> 110 × 10\^9/L 4. No clinically significant abnormalities in inflammation, coagulation, or electrolyte panels Exclusion Criteria: * Concurrent use of finasteride, minoxidil, or other hair growth treatments during the PRP treatment phase of the study * Failure to complete a minimum of 3 consecutive PRP treatment sessions as per the study protocol * Failure to complete the required follow-up assessments for any reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenic alopecia

Contacts and locations

Locations

  • The General Hospital of Western Theater Command

    Chengdu, Sichuan, 610036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.